# SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment

> **NCT06010953** · PHASE1,PHASE2 · COMPLETED · sponsor: **Jiangsu Gensciences lnc.** · enrollment: 24 (actual)

## Conditions studied

- Male
- Hemophilia A With Inhibitor
- Hemophilia B With Inhibitor
- Hemophilia

## Interventions

- **DRUG:** SS109

## Key facts

- **NCT ID:** NCT06010953
- **Lead sponsor:** Jiangsu Gensciences lnc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-12
- **Primary completion:** 2024-05-07
- **Final completion:** 2024-05-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06010953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06010953, "SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06010953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*